Multivitamin Dosage Regimens in the Prevention of Adverse Pregnancy Outcomes Among HIV-Positive Women
Multivitamin Dosage Regimens in the Prevention of Adverse Pregnancy Outcomes Among HIV-Positive Women
The purpose of this study is to examine effects of daily administration of multivitamin
 supplements at doses resembling the Recommended Dietary Allowance (RDA) during pregnancy to
 HIV positive women decreases the risks of low birth weight (<2500 g), and pre-term birth (<
 37 weeks gestation), compared to multivitamin supplements at doses above the RDA.
This is a randomized clinical trial conducted to examine effects of daily administration of
 multivitamin supplements at doses resembling the Recommended Dietary Allowance (RDA) during
 pregnancy to HIV positive women decreases the risks of low birth weight (<2500 g), and
 pre-term birth (< 37 weeks gestation), compared to multivitamin supplements at doses above
 the RDA. All women receive standard prenatal care, including nevirapine for the prevention of
 mother-to-child transmission of HIV.
Inclusion Criteria:

 - HIV-positive pregnant women who are between 12 and 27 weeks gestation who intend to stay
 in Dar es Salaam until delivery.